avastin
Roche gains new licence for blockbuster oncology drug
August 6, 2014Research and Development, Sales and Marketing EC, Roche, avastin, ovarian cancer
Roche’s blockbuster cancer treatment Avastin now has a new European licence to treat women with a certain type of ovarian …
FDA speedy review for new Avastin licence
July 16, 2014Research and Development, Sales and Marketing Cancer, Roche, avastin, cervical cancer
The FDA has granted priority review status for Roche’s Avastin (bevacizumab) plus chemotherapy in women with persistent, recurrent or metastatic …
Novartis back under microscope
June 23, 2014Medical Communications, Sales and Marketing Italy, Novartis, avastin, fraud, influenza, vaccines
Novartis is under the microscope yet again in Italy, with police visiting the company’s sites at Siena and Origgio in …
Italy eyes €1.2 billion pharma fine
May 30, 2014Sales and Marketing Novartis, Roche, avastin, off label, wet and
Italy’s health ministry says it is looking for €1.2 billion in damages from Roche and Novartis over claims that the …
EU looks at eye drug allegations
May 8, 2014Sales and Marketing EU, Lucentis, Novartis, Roche, avastin, offlabel
European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …
Roche/Novartis offices raided over anti-competitive activities
April 11, 2014Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD
French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …
IBM supercomputer could hold key to brain cancer
March 21, 2014Medical Communications, Sales and Marketing avastin, brain cancer, ibm, nygc, supercomputer
The New York Genome Center and IBM Watson have joined forces to accelerate a new era of genomic medicine, initially …
Roche lung cancer drug fails
March 3, 2014Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin
An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …
A treatment room view
February 24, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, Roche, avastin, hinsely
A little more than a year ago, Lisa Hinsley’s prospects were not good. The mother of three had been diagnosed …
Lucentis and Avastin equal in efficacy
July 19, 2013Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin
Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …
Avastin gets GBM approval
June 18, 2013Research and Development, Sales and Marketing GBM, Roche, avastin
Roche has received a major boost with the first approval in early treatment of the most aggressive form of brain …
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
Avastin shows brain cancer benefit
November 20, 2012Research and Development, Sales and Marketing Cancer, FDA, Merck, Roche, avastin, brain
In a Phase III trial, Roche’s Avastin has helped people with newly-diagnosed glioblastoma (GBM) live longer without their disease worsening. …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
